Systemic Therapy of Central Nervous System Metastases of Breast Cancer

被引：28

作者：

Leone, Jose Pablo ^{[1
]}

Lin, Nancy U. ^{[1
]}

机构：

[1] Harvard Med Sch, Dept Med Oncol, Div Breast Oncol, Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA

来源：

CURRENT ONCOLOGY REPORTS | 2019年 / 21卷 / 06期

关键词：

Breast cancer; Brain metastases; Chemotherapy; Targeted therapies; Metastatic breast cancer; LAPATINIB PLUS CAPECITABINE; GRADED PROGNOSTIC ASSESSMENT; TRASTUZUMAB EMTANSINE T-DM1; RANDOMIZED PHASE-III; BRAIN METASTASES; TUMOR SUBTYPE; LIPOSOMAL DOXORUBICIN; CNS METASTASES; SURVIVAL; TEMOZOLOMIDE;

D O I：

10.1007/s11912-019-0802-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose of the ReviewHistorically, systemic treatment options for patients with breast cancer brain metastases have been very limited. This review focuses on important considerations for systemic therapy as well as ongoing clinical trials evaluating novel agents.Recent FindingsFor patients with hormone receptor-positive brain metastases, endocrine therapy or chemotherapy options can be considered. The role of CDK4/6 inhibitors is being explored in ongoing trials. Patients with HER2-positive disease have a number of treatment options, including ado-trastuzumab emtansine (TDM1) or lapatinib-capecitabine, and there is emerging evidence of the efficacy of neratinib- and tucatinib-based chemotherapy combinations in the CNS. Triple-negative tumors may respond to chemotherapy.SummaryAlthough much progress remains to be made, a number of effective systemic treatment options are emerging, particularly for patients with HER2-positive disease. Ongoing clinical trials will help define the role of novel agents.

引用

页数：8

共 81 条

[1] TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases [J].

Anders, Carey ;

Deal, Allison M. ;

Abramson, Vandana ;

Liu, Minetta C. ;

Storniolo, Anna M. ;

Carpenter, John T. ;

Puhalla, Shannon ;

Nanda, Rita ;

Melhem-Bertrandt, Amal ;

Lin, Nancy U. ;

Marcom, P. Kelly ;

Van Poznak, Catherine ;

Stearns, Vered ;

Melisko, Michelle ;

Smith, J. Keith ;

Karginova, Olga ;

Parker, Joel ;

Berg, Jonathan ;

Winer, Eric P. ;

Peterman, Amy ;

Prat, Aleix ;

Perou, Charles M. ;

Wolff, Antonio C. ;

Carey, Lisa A. .

BREAST CANCER RESEARCH AND TREATMENT, 2014, 146 (03) :557-566

[2] The Prognostic Contribution of Clinical Breast Cancer Subtype, Age, and Race Among Patients With Breast Cancer Brain Metastases [J].

Anders, Carey K. ;

Deal, Allison M. ;

Miller, C. Ryan ;

Khorram, Carmen ;

Meng, Hong ;

Burrows, Emily ;

Livasy, Chad ;

Fritchie, Karen ;

Ewend, Matthew G. ;

Perou, Charles M. ;

Carey, Lisa A. .

CANCER, 2011, 117 (08) :1602-1611

[3] Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer The NEfERT-T Randomized Clinical Trial [J].

Awada, Ahmad ;

Colomer, Ramon ;

Inoue, Kenichi ;

Bondarenko, Igor ;

Badwe, Rajendra A. ;

Demetriou, Georgia ;

Lee, Soo-Chin ;

Mehta, Ajay O. ;

Kim, Sung-Bae ;

Bachelot, Thomas ;

Goswami, Chanchal ;

Deo, Suryanarayan ;

Bose, Ron ;

Wong, Alvin ;

Xu, Feng ;

Yao, Bin ;

Bryce, Richard ;

Carey, Lisa A. .

JAMA ONCOLOGY, 2016, 2 (12) :1557-1564

[4] Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study [J].

Bachelot, Thomas ;

Romieu, Gilles ;

Campone, Mario ;

Dieras, Veronique ;

Cropet, Claire ;

Dalenc, Florence ;

Jimenez, Marta ;

Le Rhun, Emilie ;

Pierga, Jean-Yves ;

Goncalves, Anthony ;

Leheurteur, Marianne ;

Domont, Julien ;

Gutierrez, Maya ;

Cure, Herve ;

Ferrero, Jean-Marc ;

Labbe-Devilliers, Catherine .

LANCET ONCOLOGY, 2013, 14 (01) :64-71

[5] Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer [J].

Bartsch, Rupert ;

Rottenfusser, Andrea ;

Wenzel, Catharina ;

Dieckmann, Karin ;

Pluschnig, Ursula ;

Altorjai, Gabriela ;

Rudas, Margaretha ;

Mader, Robert M. ;

Poetter, Richard ;

Zielinski, Christoph C. ;

Steger, Guenther G. .

JOURNAL OF NEURO-ONCOLOGY, 2007, 85 (03) :311-317

[6] Activity of T-DM1 in Her2-positive breast cancer brain metastases [J].

Bartsch, Rupert ;

Berghoff, Anna S. ;

Vogl, Ursula ;

Rudas, Margaretha ;

Bergen, Elisabeth ;

Dubsky, Peter ;

Dieckmann, Karin ;

Pinker, Katja ;

Bago-Horvath, Zsuzsanna ;

Galid, Arik ;

Oehler, Leopold ;

Zielinski, Christoph C. ;

Gnant, Michael ;

Steger, Guenther G. ;

Preusser, Matthias .

CLINICAL & EXPERIMENTAL METASTASIS, 2015, 32 (07) :729-737

[7]

BOOGERD W, 1992, CANCER, V69, P972, DOI 10.1002/1097-0142(19920215)69:4<972::AID-CNCR2820690423>3.0.CO

[8]

2-P

[9] Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER [J].

Brufsky, Adam M. ;

Mayer, Musa ;

Rugo, Hope S. ;

Kaufman, Peter A. ;

Tan-Chiu, Elizabeth ;

Tripathy, Debu ;

Tudor, Iulia Cristina ;

Wang, Lisa I. ;

Brammer, Melissa G. ;

Shing, Mona ;

Yood, Marianne Ulcickas ;

Yardley, Denise A. .

CLINICAL CANCER RESEARCH, 2011, 17 (14) :4834-4843

[10] Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer [J].

Burstein, Harold J. ;

Sun, Yan ;

Dirix, Luc Y. ;

Jiang, Zefei ;

Paridaens, Robert ;

Tan, Antoinette R. ;

Awada, Ahmad ;

Ranade, Anantbhushan ;

Jiao, Shunchang ;

Schwartz, Gary ;

Abbas, Richat ;

Powell, Christine ;

Turnbull, Kathleen ;

Vermette, Jennifer ;

Zacharchuk, Charles ;

Badwe, Rajendra .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (08) :1301-1307

← 1 2 3 4 5 6 7 8 9 →